Alanna Morris, MD

Assistant Professor of Medicine, Division of Cardiology

Emory University School of Medicine

Director of Heart Failure Services

Atlanta VA Medical Center


  • BS, Biology, Xavier University of Louisiana, New Orleans, LA, 2001
  • MD, Harvard University, Cambridge, MA, 2005


Dr. Alanna A. Morris joined the ECCRI faculty in 2013. Dr. Morris received her undergraduate degree in Biology from Xavier University of Louisiana, and her medical degree from the Harvard Medical School. She completed her residency at Brigham and Women’s Hospital in Boston, Massachusetts. Subsequently, she came to Emory University to complete fellowships in general cardiology, and advanced heart failure and transplant.   After completion of her fellowship training, she was appointed Assistant Professor of Medicine in the Division of Cardiology at Emory University School of Medicine.  Her clinical time is spent as the Director of Heart Failure Services at the Atlanta VA Medical Center, and as faculty for Emory’s Center for Heart Failure Therapy and Transplantation.


Dr. Morris’ research interests include studying the importance of non-modifiable risk factors such as race and gender that may contribute to excess disease in high risk populations, and identifying the role of biomarkers of oxidative stress (OS) and endothelial dysfunction in patients with heart failure with reduced ejection fraction (HFrEF). As a part of the Clinical Investigator Track of the Cardiovascular Fellowship at Emory, Dr. Morris worked under Dr. Arshed Quyyumi, who is known for his work in endothelial dysfunction and the contribution of OS to cardiovascular disease (CVD) phenotypes. During her advanced heart failure Fellowship at Emory, she began research projects with Dr. Javed Butler who serves as the deputy chief science advisor for the American Heart Association. With their mentorship, she continues to pursue research that examines the interface between biochemical markers of OS with vascular and endothelial dysfunction in HFrEF, and the importance of metabolomic signatures in determining HF progression. In particular, she also seeks to define race- and gender- based differences in these biochemical and vascular markers, and whether they contribute significantly to observed differences in HF morbidity and mortality. Finally, her research examines race- and gender-based differences in outcomes after heart transplantation and LVAD implantation.